We regularly advise our clients on the Chinese healthcare, pharmaceuticals and medical device industries. We also have extensive experience in transactions involving foreign-invested healthcare institutions in China, including:

  • Advising on the development of seniors housing and healthcare facilities
  • Advising a Beijing-based owner and operator of private hospitals and clinics
  • Advising an operator of specialty care hospitals on the provision of services in China 
  • Advising on the restructuring of a Chinese hospital management company to facilitate foreign investment

In addition, we have handled a wide range of acquisitions, joint ventures, and technology licensing transactions by multinational pharmaceutical and medical device manufacturers, such as Bristol-Myers Squibb and Hologic, Inc., and continue to advise these companies on their China operations. We have also represented the management of Techpool Bio-Pharma Co., Ltd., a Chinese pharmaceutical manufacturer, in the sale of a controlling interest in the company to a multinational pharmaceutical manufacturer.

Contacts

Sort By
Ross, Lester

Lester Ross

Partner-in-Charge, Beijing Office

+86 10 5901 6588 (t)

lester.ross@wilmerhale.com

Publications & News

View

January 9, 2014

China’s New Anti-Corruption Policies in the Health Care Industry

On December 26 and 25, 2013, respectively, China's National Health and Family Planning Commission (NHFPC) promulgated two circulars, Circular 49 and Circular 50. Circular 49 provides comprehensive anti-corruption compliance requirements to be observed by hospitals and physicians, and Circular 50 establishes a "blacklist" system on pharmaceutical and medical device providers.